NTLA-2001
Intellia Therapeutics
['cardio', 'cardiomyopathy', 'crispr']
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022 
#Stocks News Feed provides Stock Market News, and Press Releases from several sources in one feed. As an affiliate, we earn from qualifying purchases.